Mouse models of nonalcoholic fatty liver disease–associated type 2 diabetes have not provided clear results using LIGHT-deficient mice (Herrero-Cervera et al., 2019; Saunders et al., 2018), highlighting the complexity of the LIGHT network in the design of LIGHT-modulating therapeutics. Here, TNFSF14 is linked to metabolic dysfunction-associated steatotic liver disease.